Importance of Candida-bacterial polymicrobial biofilms in disease

Trends in Microbiology

Volumn 19, Issue 11, 2011, Pages 557-563

  Harriott, Melphine M ^a   Noverr, Mairi C ^b,c  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

^b Department of Oral and Craniofacial Biology   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BORIC ACID; ETHINYLESTRADIOL; ETONOGESTREL; FARNESOL; FLUCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIUM ADHERENCE; BIOFILM; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS; ENTEROCOCCUS; EXTRACELLULAR MATRIX; FUNGAL COLONIZATION; FUNGUS GROWTH; FUNGUS HYPHAE; GASTROINTESTINAL CANDIDIASIS; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LACTOBACILLUS; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; QUORUM SENSING; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STOMATITIS; STREPTOCOCCUS GORDONII; THRUSH; TOXIC SHOCK SYNDROME; VAGINA CANDIDIASIS; VAGINA MUCOSA; VAGINA MYCOSIS; VAGINA RING; WOUND HEALING; WOUND INFECTION;

ANIMALS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; COINFECTION; HUMANS; VIRULENCE;

BACTERIA (MICROORGANISMS); CANDIDA; CANDIDA ALBICANS;

EID: 80755129005     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2011.07.004     Document Type: Review

References (95)

1. Chandra J., et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 2001, 183:5385-5394.
2. Ramage G., et al. Characteristics of biofilm formation by Candida albicans. Rev. Ibero. Micol. 2001, 18:163-170.
3. Nobile C.J., et al. Function of Candida albicans adhesin Hwp1 in biofilm formation. Eukaryot. Cell 2006, 5:1604-1610.
4. Ramage G., et al. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol. Lett. 2002, 214:95-100.
5. Nobile C.J., et al. Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog. 2006, 2:e63.
6. Baillie G.S., Douglas L.J. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J. Antimicrob. Chemother. 2000, 46:397-403.
7. Nett J., et al. Beta-1,3 glucan as a test for central venous catheter biofilm infection. J. Infect. Dis. 2007, 195:1705-1712.
8. Blankenship J.R., Mitchell A.P. How to build a biofilm: a fungal perspective. Curr. Opin. Microbiol. 2006, 9:588-594.
9. Ramage G., et al. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl. Environ. Microbiol. 2002, 68:5459-5463.
10. Jabra-Rizk M.A., et al. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance. FEMS Yeast Res. 2006, 6:1063-1073.
11. Uppuluri P., et al. The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot. Cell 2010, 9:1531-1537.
12. Ramage G., et al. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 2006, 6:979-986.
13. Kojic E.M., Darouiche R.O. Candida infections of medical devices. Clin. Microbiol. Rev. 2004, 17:255-267.
14. Crump J.A., Collignon P.J. Intravascular catheter-associated infections. Eur. J. Clin. Microbiol. Infect. Dis. 2000, 19:1-8.
15. Dominic R.M., et al. Candida biofilms in medical devices: evolving trends. Kathmandu Univ. Med. J. (KUMJ) 2007, 5:431-436.
16. Dongari-Bagtzoglou A., et al. Characterization of mucosal Candida albicans biofilms. PLoS ONE 2009, 4:e7967.
17. Harriott M.M., et al. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 2010, 156:3635-3644.
18. Colonization of Mucosal Surfaces 2005, ASM Press. J. Natero (Ed.).
19. Shirtliff M.E., et al. Cross-kingdom interactions: Candida albicans and bacteria. FEMS Microbiol. Lett. 2009, 299:1-8.
20. Wargo M.J., Hogan D.A. Fungal-bacterial interactions: a mixed bag of mingling microbes. Curr. Opin. Microbiol. 2006, 9:359-364.
21. Thein Z.M., et al. Community lifestyle of Candida in mixed biofilms: a mini review. Mycoses 2009, 52:467-475.
22. Klotz S.A., et al. Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn. Microbiol. Infect. Dis. 2007, 59:401-406.
23. Pulimood S., et al. Polymicrobial candidemia. Diagn. Microbiol. Infect. Dis. 2002, 44:353-357.
24. Adam B., et al. Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J. Med. Microbiol. 2002, 51:344-349.
25. Al-Fattani M.A., Douglas L.J. Penetration of Candida biofilms by antifungal agents. Antimicrob. Agents Chemother. 2004, 48:3291-3297.
26. Al-Fattani M.A., Douglas L.J. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 2006, 55:999-1008.
27. Guerra-Romero L., et al. Polymicrobial fungemia: microbiology, clinical features, and significance. Rev. Infect. Dis. 1989, 11:208-212.
28. Dyess D.L., et al. Candida sepsis. Implications of polymicrobial blood-borne infection. Arch. Surg. 1985, 120:345-348.
29. Cassat J.E., et al. Investigation of biofilm formation in clinical isolates of Staphylococcus aureus. Methods Mol. Biol. 2007, 391:127-144.
30. Harriott M.M., Noverr M.C. Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance. Antimicrob. Agents Chemother. 2009, 53:3914-3922.
31. Harriott M.M., Noverr M.C. Ability of Candida albicans mutants to induce Staphylococcus aureus vancomycin resistance during polymicrobial biofilm formation. Antimicrob. Agents Chemother. 2010, 54:3746-3755.
32. Peters B.M., et al. Microbial interactions and differential protein expression in Staphylococcus aureus-Candida albicans dual-species biofilms. FEMS Immunol. Med. Microbiol. 2010, 59:493-503.
33. Nobile C.J., et al. Complementary adhesin function in C. albicans biofilm formation. Curr. Biol. 2008, 18:1017-1024.
34. Carlson E. Synergistic effect of Candida albicans and Staphylococcus aureus on mouse mortality. Infect. Immun. 1982, 38:921-924.
35. Carlson E. Enhancement by Candida albicans of Staphylococcus aureus, Serratia marcescens, and Streptococcus faecalis in the establishment of infection in mice. Infect. Immun. 1983, 39:193-197.
36. Klaerner H.G., et al. Candida albicans and Escherichia coli are synergistic pathogens during experimental microbial peritonitis. J. Surg. Res. 1997, 70:161-165.
37. Carlson E. Effect of strain of Staphylococcus aureus on synergism with Candida albicans resulting in mouse mortality and morbidity. Infect. Immun. 1983, 42:285-292.
38. Carlson E.C. Synergism of Candida albicans and delta toxin producing Staphylococcus aureus on mouse mortality and morbidity: protection by indomethacin. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] 1988, 269:377-386.
39. Carlson E., Johnson G. Protection by Candida albicans of Staphylococcus aureus in the establishment of dual infection in mice. Infect. Immun. 1985, 50:655-659.
40. Sobel J.D. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann. N. Y. Acad. Sci. 1988, 544:547-557.
41. Sobel J.D. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin. Infect. Dis. 1992, 14(Suppl. 1):S148-S153.
42. Kent H.L. Epidemiology of vaginitis. Am. J. Obstet. Gynecol. 1991, 165:1168-1175.
43. Noverr M.C., Huffnagle G.B. Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect. Immun. 2004, 72:6206-6210.
44. Strus M., et al. The in vitro activity of vaginal Lactobacillus with probiotic properties against Candida. Infect. Dis. Obstet. Gynecol. 2005, 13:69-75.
45. Boris S., Barbes C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect. 2000, 2:543-546.
46. Falagas M.E., et al. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J. Antimicrob. Chemother. 2006, 58:266-272.
47. Swidsinski A., et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am. J. Obstet. Gynecol. 2008, 198. 97.e1-6.
48. van der Meijden W.I., et al. Descriptive light and electron microscopy of normal and clue-cell-positive discharge. Gynecol. Obstet. Invest. 1988, 25:47-57.
49. Scott T.G., et al. Electron microscopy of adhesive interactions between Gardnerella vaginalis and vaginal epithelial cells, McCoy cells and human red blood cells. J. Gen. Microbiol. 1989, 135:475-480.
50. Buchta V., Spacek J. Microbiological findings in patients with recurrent vulvovaginal candidiasis in the Hradec Kralove Faculty Hospital 1995-2002. Ceska Gynekol. 2004, 69:7-14. (in Czech).
51. Esim Buyukbayrak E., et al. Diagnosis of vulvovaginitis: comparison of clinical and microbiological diagnosis. Arch. Gynecol. Obstet. 2010, 282:515-519.
52. De Seta F., et al. Antifungal mechanisms supporting boric acid therapy of Candida vaginitis. J. Antimicrob. Chemother. 2009, 63:325-336.
53. Pal Z., et al. Biofilm formation on intrauterine devices in relation to duration of use. J. Med. Microbiol. 2005, 54:1199-1203.
54. Guerreiro D., et al. Sexually transmitted diseases and reproductive tract infections among contraceptive users. Int. J. Gynaecol. Obstet. 1998, 63(Suppl. 1):S167-S173.
55. Ferraz do Lago R., et al. Follow-up of users of intrauterine device with and without bacterial vaginosis and other cervicovaginal infections. Contraception 2003, 68:105-109.
56. Grimes D.A. Intrauterine devices and pelvic inflammatory disease: recent developments. Contraception 1987, 36:97-109.
57. Farley T.M., et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992, 339:785-788.
58. Oddsson K., et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005, 71:176-182.
59. White S., Larsen B. Candida albicans morphogenesis is influenced by estrogen. Cell. Mol. Life Sci. 1997, 53:744-749.
60. James G.A., et al. Biofilms in chronic wounds. Wound Repair Regen. 2008, 16:37-44.
61. Dowd S.E., et al. Survey of fungi and yeast in polymicrobial infections in chronic wounds. J. Wound Care 2011, 20:40-47.
62. Leake J.L., et al. Identification of yeast in chronic wounds using new pathogen-detection technologies. J. Wound Care 2009, 18:103-104. 106, 108.
63. Greenspan D., et al. Oral mucosal lesions and HIV viral load in the Women's interagency HIV study (WIHS). J. Acquir. Immune Defic. 2000, 25:44-50.
64. Nielsen H., et al. Oral candidiasis and immune status of HIV-infected patients. J. Oral Pathol. Med. 1994, 23:140-143.
65. Sangeorzan J.A., et al. Epidemiology of oral candidiasis in HIV infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med. 1994, 97:339-346.
66. Schuman P., et al. Oral lesions among women living with or at risk for HIV infection. Am. J. Med. 1998, 104:559-563.
67. Allen C.M., Beck F.M. Differences in mucosal reaction related to Candida albicans isolates. J. Oral Pathol. 1987, 16:89-93.
68. Wheeler R.T., et al. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog. 2008, 4:e1000227.
69. Netea M.G., et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J. Clin. Invest. 2006, 116:1642-1650.
70. Cheng S.C., et al. The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans. J. Leukoc. Biol. 2011, 90:357-366.
71. Ferwerda B., et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 2009, 361:1760-1767.
72. Conti H.R., et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 2009, 206:299-311.
73. Budtz-Jorgensen E. The role of Candida albicans in the development of stomatitis in denture wearers. Med. Hyg. (Geneve) 1975, 33:1434-1435. (in French).
74. Arendorf T.M., Walker D.M. Denture stomatitis: a review. J. Oral Rehabil. 1987, 14:217-227.
75. Cumming C.G., et al. Denture stomatitis in the elderly. Oral Microbiol. Immunol. 1990, 5:82-85.
76. Nett J.E., et al. Development and validation of an in vivo Candida albicans biofilm denture model. Infect. Immun. 2010, 78:3650-3659.
77. Lee H., et al. Fabrication of a multi-applicable removable intraoral denture system for rodent research. J. Oral Rehabil. 2011, 38:686-690.
78. Bamford C.V., et al. Streptococcus gordonii modulates Candida albicans biofilm formation through intergeneric communication. Infect. Immun. 2009, 77:3696-3704.
79. Silverman R.J., et al. Interaction of Candida albicans cell wall Als3 protein with Streptococcus gordonii SspB adhesin promotes development of mixed-species communities. Infect. Immun. 2010, 78:4644-4652.
80. Nobbs A.H., et al. Heterologous expression of Candida albicans cell wall-associated adhesins in Saccharomyces cerevisiae reveals differential specificities in adherence and biofilm formation and in binding oral Streptococcus gordonii. Eukaryot. Cell 2010, 9:1622-1634.
81. Williamson D.R., et al. The relationship between Candida species cultured from the respiratory tract and systemic inflammation in critically ill patients with ventilator-associated pneumonia. Can. J. Anaesth. 2011, 58:275-284.
82. Azoulay E., et al. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 2006, 129:110-117.
83. Hogan D.A., Kolter R. Pseudomonas-Candida interactions: an ecological role for virulence factors. Science 2002, 296:2229-2232.
84. Morales D.K., et al. Antifungal mechanisms by which a novel Pseudomonas aeruginosa phenazine toxin kills Candida albicans in biofilms. Mol. Microbiol. 2010, 78:1379-1392.
85. Kerr J.R., et al. Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J. Clin. Pathol. 1999, 52:385-387.
86. Brand A., et al. Cell wall glycans and soluble factors determine the interactions between the hyphae of Candida albicans and Pseudomonas aeruginosa. FEMS Microbiol. Lett. 2008, 287:48-55.
87. Leclair L.W., Hogan D.A. Mixed bacterial-fungal infections in the CF respiratory tract. Med. Mycol. 2010, 48(Suppl. 1):S125-S132.
88. Roux D., et al. Candida albicans impairs macrophage function and facilitates Pseudomonas aeruginosa pneumonia in rat. Crit. Care Med. 2009, 37:1062-1067.
89. Kleinegger C.L., et al. Frequency, intensity, species, and strains of oral Candida vary as a function of host age. J. Clin. Microbiol. 1996, 34:2246-2254.
90. Soll D.R., et al. Genetic dissimilarity of commensal strains of Candida spp. carried in different anatomical locations of the same healthy women. J. Clin. Microbiol. 1991, 29:1702-1710.
91. Samonis G., et al. Prospective study of the impact of broad-spectrum antibiotics on the yeast flora of the human gut. Eur. J. Clin. Microbiol. 1994, 13:665-667.
92. Anaissie E.J., Bodey G.P. Fungal infections in patients with cancer. Pharmacotherapy 1990, 10:164S-169S.
93. Noverr M.C., et al. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect. Immun. 2004, 72:4996-5003.
94. Noverr M.C., et al. Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13. Infect. Immun. 2005, 73:30-38.
95. White S.J., et al. Self-regulation of Candida albicans population size during GI colonization. PLoS Pathog. 2007, 3:e184.